TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24869609

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion preoperatively and throughout surgery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 36
Study: 23115768

Group type: EXPERIMENTAL
Intervention: Mucoperiosteal flap
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flapless buccal surgery
Number of subjects: 40
Study: 20682671

Group type: COMPARATOR
Intervention: Immediate-release (IR) prednisone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Modified-release (MR) prednisone
Number of subjects: 28
Study: 17704660

Group type: EXPERIMENTAL
Intervention: Assay-directed therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Physician's-choice chemotherapy
Number of subjects: 180
Study: 15353050

Group type: EXPERIMENTAL
Intervention: CRP rapid test used by GPs (77% of GPs, n = 281)
Number of subjects: 1444

Group type: COMPARATOR
Intervention: No CRP rapid test used by GPs (23% of GPs)
Number of subjects: 1444
Study: 11396371

Group type: EXPERIMENTAL
Intervention: Unkei-to
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 9926634

Group type: EXPERIMENTAL
Intervention: Twin Block appliance
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bionator appliance
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bass appliance
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: All appliance groups
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 7851219

Group type: EXPERIMENTAL
Intervention: tolrestat (200 mg once daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study: 3183072

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31837066

Group type: EXPERIMENTAL
Intervention: Formal Sector Social Health Insurance Programme (FSSHIP)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Out-of-pocket (OOP) payments
Number of subjects: 333
Study: 29035220

Group type: EXPERIMENTAL
Intervention: Robot-applied force vector field intervention
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (trained without forces)
Number of subjects: 11
Study: 28727643

Group type: EXPERIMENTAL
Intervention: School-based intervention delivered by teachers
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190
Study: 26027780

Group type: EXPERIMENTAL
Intervention: Illiterate patients
Number of subjects: 422

Group type: COMPARATOR
Intervention: Literates
Number of subjects: 422

Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 422

Group type: COMPARATOR
Intervention: History of foot ulcer
Number of subjects: 422
Study: 23883161

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 135
Study: 21951770

Group type: EXPERIMENTAL
Intervention: Facilitation intervention targeting healthcare staff and community representatives over 3 years.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 90
Study: 18303059

Group type: EXPERIMENTAL
Intervention: Asymmetric-asymptomatic group (n=6)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Asymmetric-symptomatic group (n=5)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 34
Study: 17144957

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided location of heel spur for ESWT
Number of subjects: 41

Group type: COMPARATOR
Intervention: Patient location of maximal point of tenderness for ESWT
Number of subjects: 41
Study: 14628987

Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no psychoeducation)
Number of subjects: 25
Study: 10863680

Group type: EXPERIMENTAL
Intervention: Hardiness, avoidance coping, and approach coping
Number of subjects: 381
Study: 9094877

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 8
Study: 8456144

Group type: EXPERIMENTAL
Intervention: Combined training (n = 12): vigorous program of lower‐extremity strengthening, walking briskly for 20 minutes, and postural control exercises (including tai chi movements)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Flexibility training (n = 9): performed postural control exercises weekly
Number of subjects: 21
Study: 3541091

Group type: EXPERIMENTAL
Intervention: sobrerol 300 mg b.i.d. for 3 months
Number of subjects: 706

Group type: COMPARATOR
Intervention: placebo b.i.d. for 3 months
Number of subjects: 706
Study: 31167863

Group type: EXPERIMENTAL
Intervention: ICAN QUIT in Pregnancy intervention (three 1-hour webinar sessions, educational resource package, and free oral NRT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ICAN QUIT in Pregnancy intervention
Number of subjects: 50
Study: 29893488

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 27310332

Group type: EXPERIMENTAL
Intervention: CTP-499 (600 mg orally once daily for 2 weeks, then twice daily for 2 additional weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (matching tablets)
Number of subjects: 33
Study: 25209344

Group type: EXPERIMENTAL
Intervention: Mobi‐C disc prosthesis replacement
Number of subjects: 111

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 111
Study: 23107225

Group type: EXPERIMENTAL
Intervention: Incredible Years parent training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20923244

Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin 50 mg/500 mg FDC tablet
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sitagliptin 50 mg and metformin 500 mg co-administration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin 50 mg/1000 mg FDC tablet
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sitagliptin 50 mg and metformin 1000 mg co-administration
Number of subjects: 48
Study: 18611989

Group type: EXPERIMENTAL
Intervention: Cumulative number of contrast enhancing lesions (CEL) evolving into a persistent black hole (PBH) after 3 months
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Ring enhancing lesions
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Lesions larger than 10 mm
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Periventricular CELs
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Statistical simulation for sample sizes
Number of subjects: 169
Study: 15957835

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) - 40 ml intravenous injection, once a day for 7 days
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group - PCI only
Number of subjects: 93
Study: 11818154

Group type: EXPERIMENTAL
Intervention: Leishvacin plus rhGM‐CSF
Number of subjects: 56

Group type: COMPARATOR
Intervention: Leishvacin plus placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 56
Study: 10190773

Group type: EXPERIMENTAL
Intervention: Simulated front‐crawl arm‐pulling
Number of subjects: 16

Group type: COMPARATOR
Intervention: Simulated leg‐kicking
Number of subjects: 16
Study: 7759696

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (6 g of n‐3 fatty acids)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Olive oil capsules (control)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fish oil capsules
Number of subjects: 59
Study: 2322153

Group type: EXPERIMENTAL
Intervention: Vasocon‐A (0.05% naphazoline hydrochloride and 0.5% antazoline phosphate)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.05% naphazoline
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5% antazoline
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 365665

Group type: EXPERIMENTAL
Intervention: Antacid (aluminum‐magnesium hydroxide tablets, 800 mg seven times per day)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sulpiride (hypothalamic neurolaptic)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Antacid-sulpiride combination
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 30610279

Group type: EXPERIMENTAL
Intervention: R-CHOP plus 8 doses of rituximab
Number of subjects: 616
Study: 27810902

Group type: EXPERIMENTAL
Intervention: TT4‐S (standard arm)
Number of subjects: 289

Group type: COMPARATOR
Intervention: TT4‐L (light arm)
Number of subjects: 289
Study: 25579609

Group type: EXPERIMENTAL
Intervention: CBM-I with 0 letters missing
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: CBM-I with 1 letter missing
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: CBM-I with 2 letters missing
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: CBM-I with 3 letters missing
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control condition (half scenarios ended positively, half negatively)
Number of subjects: 350
Study: 23703722

Group type: EXPERIMENTAL
Intervention: Calcium supplements (up to 1000 mg/d)
Number of subjects: 9033

Group type: EXPERIMENTAL
Intervention: Higher total calcium intake (per 500 mg increase)
Number of subjects: 9033

Group type: COMPARATOR
Intervention: Vitamin D intake
Number of subjects: 9033
Study: 23864987

Group type: EXPERIMENTAL
Intervention: Pharmacy-based asthma care service via telephone
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 98
Study: 19029962

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (non-rituximab-treated patients)
Number of subjects: 6
Study: 17221265

Group type: EXPERIMENTAL
Intervention: Combined SSEP/MEP monitoring
Number of subjects: 100

Group type: COMPARATOR
Intervention: MEP monitoring
Number of subjects: 100
Study: 15174791

Group type: EXPERIMENTAL
Intervention: Filtered infusions via a central catheter
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-filtered infusions via a central catheter
Number of subjects: 88
Study: 11423928

Group type: EXPERIMENTAL
Intervention: Yoghurt with 10(8) bacteria/ml
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Products with reduced population of live flora (10(6) and 10(5) bacteria/ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 24

Group type: COMPARATOR
Intervention: Heat-treated yoghurt (<15 bacteria/ml)
Number of subjects: 24
Study: 9425382

Group type: EXPERIMENTAL
Intervention: Once daily amikacin (15 mg/kg, n = 27)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Twice daily amikacin (7.5 mg/kg, n = 27)
Number of subjects: 54
Study: 8381943

Group type: EXPERIMENTAL
Intervention: Cyclosporin and prednisolone (group Cy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Azathioprine and prednisolone (group Az)
Number of subjects: 30
Study: 2893638

Group type: EXPERIMENTAL
Intervention: Temelastine (100 mg, oral, twice daily for 7 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (oral, twice daily for 7 days)
Number of subjects: 10
Study: 2910421

Group type: EXPERIMENTAL
Intervention: Intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; triple-drug chemoprophylaxis of the CNS using methotrexate, hydrocortisone, and cytosine arabinoside.
Number of subjects: 430

Group type: COMPARATOR
Intervention: Cranial irradiation and intrathecal methotrexate.
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; triple-drug chemoprophylaxis of the CNS.
Number of subjects: 430
Study: 31393402

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate at 2 grams/hour
Number of subjects: 62

Group type: COMPARATOR
Intervention: Magnesium sulfate at 1 gram/hour
Number of subjects: 62
Study: 28944527

Group type: EXPERIMENTAL
Intervention: Pure mirror exposure (n=17)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Guided mirror exposure (n=18)
Number of subjects: 35
Study: 24652221

Group type: EXPERIMENTAL
Intervention: Vitamin B12 for 2 months followed by folic acid for 2 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Folic acid for 2 months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Diffusive dialysis
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Convective dialysis
Number of subjects: 74
Study: 24135139

Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAAs) 20 g twice daily for 1 week before and 2 weeks after TKA
Number of subjects: 28
Study: 21670770

Group type: EXPERIMENTAL
Intervention: APC combined with high dose rate (HDR) brachytherapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: APC combined with photodynamic therapy (PDT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: APC alone
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: APC combined with HDR
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: APC combined with PDT
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 19494744

Group type: EXPERIMENTAL
Intervention: Consecutive pedicle screw placement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interval pedicle screw placement
Number of subjects: 30
Study: 16756732

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 50
Study: 15118522

Group type: COMPARATOR
Intervention: Placebo group from the PROWESS trial
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Protein C levels
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Interleukin-6 levels
Number of subjects: 840
Study: 11026657

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/wk for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9301397

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study: 8112439

Group type: EXPERIMENTAL
Intervention: Oral terfenadine (180 mg q.d., for three days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3013967

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 0

Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D3 (25-OHD3)
Number of subjects: 0
Study: 31735180

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 92

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 92
Study: 28609505

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allografts (ADMs) with coronally advanced flaps
Number of subjects: 0
Study: 26017871

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg once a day for 30 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23104710

Group type: EXPERIMENTAL
Intervention: OK-432 (Sapylin) applied to the axillary fossa plus placement of closed suction drainage
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group with placement of closed suction drainage only
Number of subjects: 111
Study: 21969505

Group type: EXPERIMENTAL
Intervention: Traditional and new prognostic factors evaluated (including FISH, IGHV mutation status, ZAP‐70 expression)
Number of subjects: 930
Study: 17955230

Group type: EXPERIMENTAL
Intervention: CYP2C9*2 or CYP2C9*3
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CYP2C9*3
Number of subjects: 103

Group type: COMPARATOR
Intervention: CYP2C9*1*1
Number of subjects: 103
Study: 17145679

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (lavender, chamomile, rosemary, lemon), 20 min sessions, 3 times per week for two 3-week periods with a 1-week break
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no aromatherapy massage)
Number of subjects: 36
Study: 14665499

Group type: EXPERIMENTAL
Intervention: Highly efficacious treatment (n = 257)
Number of subjects: 2971

Group type: EXPERIMENTAL
Intervention: Moderately efficacious treatment (n = 965)
Number of subjects: 2971

Group type: EXPERIMENTAL
Intervention: Mildly efficacious treatment (n = 891)
Number of subjects: 2971
Study: 10365809

Group type: EXPERIMENTAL
Intervention: Standard-dose ursodeoxycholic acid (13-15 mg x kg(‐1) x day(‐1))
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (23-25 mg x kg(‐1) x day(‐1))
Number of subjects: 155

Group type: COMPARATOR
Intervention: Low-dose ursodeoxycholic acid (5-7 mg x kg(‐1) x day(‐1))
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: All doses of ursodeoxycholic acid
Number of subjects: 155
Study: 7729434

Group type: EXPERIMENTAL
Intervention: Weight lifting programme 5 days each week for 3 years (W-group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Weight lifting programme for 3 years with additional running programme (2 miles of jogging once a week during the 3rd year) (R1-group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Weight lifting programme during the 1st year and combined jogging and weight lifting programme during the 2nd and 3rd years (R2-group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All groups (W, R1, R2)
Number of subjects: 26
Study: 1646292

Group type: EXPERIMENTAL
Intervention: cisplatin, etoposide (VP‐16) + methylglyoxal bisguanylhydrazone (MGBG; PVp)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: cisplatin, etoposide (VP‐16) + methylglyoxal bisguanylhydrazone (MGBG; PVpM)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: cisplatin, vinblastine (PVe)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: PVe alternating with vinblastine, mitomycin (PVeMi)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: fluorouracil, vincristine, mitomycin/cyclophosphamide, doxorubicin, cisplatin (FOMi/CAP)
Number of subjects: 680
Study: 7104156

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control values
Number of subjects: 10
Study: 31956914

Group type: EXPERIMENTAL
Intervention: Self-reported sleep duration
Number of subjects: 3144

Group type: EXPERIMENTAL
Intervention: Longer sleep duration (using Mendelian randomization)
Number of subjects: 3144
Study: 30206091

Group type: EXPERIMENTAL
Intervention: Legally styled consent form with 55 risks identified in the world literature
Number of subjects: 220

Group type: COMPARATOR
Intervention: Medically styled consent form with 13 serious or most common risks
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Legally styled consent form
Number of subjects: 220

Group type: COMPARATOR
Intervention: Medically styled consent form
Number of subjects: 220
Study: 26660707

Group type: EXPERIMENTAL
Intervention: Alternating norfloxacin and rifaximin
Number of subjects: 334

Group type: COMPARATOR
Intervention: Norfloxacin alone
Number of subjects: 334

Group type: COMPARATOR
Intervention: Rifaximin alone
Number of subjects: 334

Group type: COMPARATOR
Intervention: Norfloxacin and rifaximin
Number of subjects: 334
Study: 23906550

Group type: EXPERIMENTAL
Intervention: Preventive home visit
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Senior group meetings
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control
Number of subjects: 459
Study: 22324772

Group type: EXPERIMENTAL
Intervention: LipiFlow® Thermal Pulsation System treatment
Number of subjects: 21
Study: 21035609

Group type: EXPERIMENTAL
Intervention: 5-week couple therapy intervention (n=18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Waitlist control group (n=17)
Number of subjects: 35
Study: 18727648

Group type: EXPERIMENTAL
Intervention: Successful drug withdrawal
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Duration of migraine with more than eight headache days/month
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Higher frequency of migraine after drug withdrawal
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Greater number of previous preventive treatments
Number of subjects: 83
Study: 16104447

Group type: EXPERIMENTAL
Intervention: Chest physical therapy (CPT) after thoracoscopic surgery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chest physical therapy (CPT) after thoracotomy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Thoracoscopic surgery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 36
Study: 12215965

Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (500 I.U. daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exhaustive treadmill exercise
Number of subjects: 9
Study: 9689556

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (150 IU/kg per dose, increasing to 300 IU/kg per dose, every 3 weeks for 6 months)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 8107991

Group type: EXPERIMENTAL
Intervention: Gd-DOTA
Number of subjects: 300

Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both Gd-DOTA and Gd-DTPA
Number of subjects: 300
Study: 2669665

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum (4 mg), n = 92
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum (4 mg), n = 64 (daily users)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo gum, n = 69 (daily users)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum
Number of subjects: 182
Study: 786820

Group type: EXPERIMENTAL
Intervention: Sulpiride (150 mg daily for the first week, increased to 225 mg in the second week)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Chlordiazepoxide (30 mg daily for the first week, increased to 45 mg in the second week)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 73

Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 73
Study: 30552176

Group type: EXPERIMENTAL
Intervention: Lutikizumab 200 mg subcutaneously every 2 weeks for 24 weeks
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Lutikizumab
Number of subjects: 132
Study: 28579756

Group type: EXPERIMENTAL
Intervention: Body Lipid (BL)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: COMPARATOR
Intervention: Armolipid Plus® (AM)
Number of subjects: 158